You are here: Industry Insights > liver

News List

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress PharmaSources
June 05, 2024
Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
Castle Creek Biosciences Acquires Novavita Thera contractpharma
January 10, 2022
Expands cell and gene therapy platform and development pipeline to address rare liver diseases.
Gilead Sciences Announces Launch of Asia Pacific ALL4LIVER Grant 2021 prnasia
July 28, 2021
Gilead Sciences, Inc. today announced the launch of the 2021 Gilead Asia Pacific ALL4LIVER Grant, a new grant program to support local communities in strengthening liver disease education efforts across Asia Pacific.
FDA Approves Drug for Severe Itching in Patients Liver Disease americanpharmaceuticalreview
July 22, 2021
FDA has approved Bylvay (odevixibat), the first treatment for pruritus (moderate to severe itching) in patients aged three months and older with progressive familial intrahepatic cholestasis (PFIC), a rare progressive liver disease that typically ...
New therapies will overcome unmet needs in hepatocellular carcinoma: GlobalData expresspharma
December 14, 2020
They have different mechanisms of action and are aiming to meet needs in different treatment settings.
MYR Pharmaceuticals receives conditional marketing authorisation by European Commission for HEPCLUDEX pharmaceutical-business-review
August 07, 2020
MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce that EC has granted CMA for their lead compound HEPCLUDEX.
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial americanpharmaceuticalreview
May 06, 2020
Lipocine announced that the U.S. Food & Drug Administration (FDA) has accepted the Company's Investigational New Drug application (IND) to initiate a Phase 2 proof-of-concept study to evaluate the therapeutic potential of LPCN 1148.
NGM Bio Announces Positive Preliminary Topline Liver Histology of Aldafermin in NASH Patients americanpharmaceuticalreview
March 10, 2020
NGM Biopharmaceuticals announced positive preliminary topline results from the 24-week double-blind, randomized, placebo-controlled cohort (Cohort 4) of an adaptive Phase 2 study evaluating the efficacy ...
Promethera closes Series D funding round to support expansion pharmaceutical-technology
December 17, 2019
Cell-based drugs developer Promethera Biosciences has closed a Series D financing round to support its expansion in Asian markets, along with the development of liver disease programmes.
Curcumin and Non-alcoholic Fatty Liver Disease (NAFLD) (2) LIN ZHANG
November 24, 2019
NAFLD has been associated with metabolic disorders, and many confounders such as hyperlipidemia, hypertension, obesity, and diabetes.

Previous page 1 2 3 Next page